China Acromegaly Organization
Guangzhou, Guangdong, 510000, China
Location status: Recruiting
Location contact
Ron Xie, Master
CONTACT
Zhiyong Chen, Doctor
CONTACT
NCT Number: NCT03158090
This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Guangzhou, Guangdong, 510000, China
Location status: Recruiting
Ron Xie, Master
CONTACT
Zhiyong Chen, Doctor
CONTACT
The study was designed to answer some of the most important questions about the treatment modalities of acromegaly, the relevance of these treatment modalities to patients' clinical outcomes and the economic impact of treatment programs on patients. These answers may be of great help to the treatment of these populations and may also help to make treatment and related health decisions in the future.
This study only collects the patient's medical information during the study and does not interfere with the patient's treatment. Each patient will be assigned a unique patient identification number for the study. The sites will maintain a confidential decode list that enables the study staff at the site to link the assigned patient identification number with the patient's medical records for extraction of study-required data. These registries will be maintained following International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and the respective local privacy laws and requirements.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
Other names: Lanreotide
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
Time frame: 30 yeas
To compare overall survival of acromegaly in China between receiving surgery, drug and radiotherapeutics treatment
Time frame: 30 years
To compare control required GH level of different treatment models (surgery, drug and radiotherapeutics treatment) in patients with acromegaly in China
Time frame: 30 years
To compare cost for acromegaly of different treatment models (surgery, drug and radiotherapeutics treatment) in patients with acromegaly in China
Ginkgo Leaf Center for Rare Disorders
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07583563
Acromegaly, Bone Diseases
Aachen, Germany
View Trial DetailsNCT00461188
Acromegaly, Bone Diseases
Leicester, United Kingdom
View Trial DetailsNCT07037420
Acromegaly, Bone Diseases
Los Angeles, California, United States
View Trial DetailsNCT07195175
Acromegaly, Bone Diseases
Tempe, Arizona, United States
View Trial Details